381 related articles for article (PubMed ID: 28257315)
21. Linkage analysis of alpha 1-antitrypsin deficiency: lessons for complex diseases.
Silverman EK; Mosley JD; Rao DC; Palmer LJ; Province MA; Elston RC; Weiss ST; Campbell EJ
Hum Hered; 2001; 52(4):223-32. PubMed ID: 11713419
[TBL] [Abstract][Full Text] [Related]
22. Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.
Faner R; Agustí Á
Ann Am Thorac Soc; 2016 Dec; 13 Suppl 2():S466-S470. PubMed ID: 28005422
[TBL] [Abstract][Full Text] [Related]
23. [Development of Stratified and Personalized Medicine Based on Pharmacogenomic and Pharmacokinetic Analyses].
Hirai K
Yakugaku Zasshi; 2019; 139(10):1253-1258. PubMed ID: 31582608
[TBL] [Abstract][Full Text] [Related]
24. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.
Greulich T
COPD; 2017 Mar; 14(sup1):S8-S11. PubMed ID: 28306355
[TBL] [Abstract][Full Text] [Related]
25. [From COPD definitions to COPD phenotypes].
Burgel PR
Presse Med; 2014 Dec; 43(12 Pt 1):1337-43. PubMed ID: 25448122
[TBL] [Abstract][Full Text] [Related]
26. [Familial predisposition to chronic obstructive pulmonary disease].
Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 2009; 77(4):407-10. PubMed ID: 19722147
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Alpha-1 Antitrypsin Deficiency.
Strange C; Beiko T
Semin Respir Crit Care Med; 2015 Aug; 36(4):470-7. PubMed ID: 26238635
[TBL] [Abstract][Full Text] [Related]
28. [Biologic agents in COPD management].
Gueçamburu M; Zysman M
Rev Mal Respir; 2024 Feb; 41(2):127-138. PubMed ID: 38129268
[TBL] [Abstract][Full Text] [Related]
29. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
[TBL] [Abstract][Full Text] [Related]
30. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
Kueppers F
Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
[TBL] [Abstract][Full Text] [Related]
31. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.
Strange C; Senior RM; Sciurba F; O'Neal S; Morris A; Wisniewski SR; Bowler R; Hochheiser HS; Becich MJ; Zhang Y; Leader JK; Methé BA; Kaminski N; Sandhaus RA;
Ann Am Thorac Soc; 2015 Oct; 12(10):1551-60. PubMed ID: 26153726
[TBL] [Abstract][Full Text] [Related]
32. Novel therapeutic strategy in the management of COPD: a systems medicine approach.
Lococo F; Cesario A; Del Bufalo A; Ciarrocchi A; Prinzi G; Mina M; Bonassi S; Russo P
Curr Med Chem; 2015; 22(32):3655-75. PubMed ID: 26337103
[TBL] [Abstract][Full Text] [Related]
33. COPD: To Be or Not to Be, That is the Question.
Polverino F; Sam A; Guerra S
Am J Med; 2019 Nov; 132(11):1271-1278. PubMed ID: 31152719
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.
Montuschi P; Malerba M; Santini G; Miravitlles M
Drug Discov Today; 2014 Dec; 19(12):1928-35. PubMed ID: 25182512
[TBL] [Abstract][Full Text] [Related]
35. Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Hoogendoorn M; Feenstra TL; Asukai Y; Briggs AH; Borg S; Dal Negro RW; Hansen RN; Jansson SA; Leidl R; Risebrough N; Samyshkin Y; Wacker ME; Rutten-van Mölken MPMH
Value Health; 2016; 19(6):800-810. PubMed ID: 27712708
[TBL] [Abstract][Full Text] [Related]
36. The Promise of Observational Studies (ECLIPSE, SPIROMICS, and COPDGene) in Achieving the Goal of Personalized Treatment of Chronic Obstructive Pulmonary Disease.
Rennard SI
Semin Respir Crit Care Med; 2015 Aug; 36(4):478-90. PubMed ID: 26238636
[TBL] [Abstract][Full Text] [Related]
37. [Lack of effect of substitution therapy of alpha1-antitrypsin deficiency].
Dahl R; Hilberg O; Løkke A; Pedersen L; Ringbæk T; Titlestad I
Ugeskr Laeger; 2011 Oct; 173(42):2645-7. PubMed ID: 22027165
[TBL] [Abstract][Full Text] [Related]
38. [Personalised COPD care: Where are we going?].
Roche N; Martin C; Burgel PR
Rev Pneumol Clin; 2018 Oct; 74(5):315-326. PubMed ID: 30316649
[TBL] [Abstract][Full Text] [Related]
39. Walking towards personalized medicine in pulmonary rehabilitation: Comorbidities and COPD.
Evans RA
Chron Respir Dis; 2016 Aug; 13(3):284-5. PubMed ID: 27488126
[No Abstract] [Full Text] [Related]
40. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
